Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported outcomes: what really matters to patients?
Hasanov E, Caceres JOH, Maskens DA, Giles RH, Schmitt AM. Hasanov E, et al. Lancet Oncol. 2022 May;23(5):e198. doi: 10.1016/S1470-2045(22)00156-5. Lancet Oncol. 2022. PMID: 35489342 No abstract available.
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. Hasanov E, et al. CA Cancer J Clin. 2022 Sep;72(5):454-489. doi: 10.3322/caac.21729. Epub 2022 Jun 16. CA Cancer J Clin. 2022. PMID: 35708940 Free article. Review.
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Alhalabi O, et al. Among authors: hasanov e. Int J Cancer. 2021 Jul 15;149(2):387-393. doi: 10.1002/ijc.33560. Epub 2021 Mar 24. Int J Cancer. 2021. PMID: 33739450 Free article.
Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.
Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Kaseb AO, et al. Among authors: hasanov e. J Hepatocell Carcinoma. 2022 Oct 11;9:1065-1079. doi: 10.2147/JHC.S369951. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 36254201 Free PMC article.
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM. Jonasch E, et al. Among authors: hasanov e. Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676. Ann Oncol. 2017. PMID: 28049139 Free PMC article. Clinical Trial.
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Jonasch E, et al. Among authors: hasanov e. J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11. J Clin Oncol. 2018. PMID: 29641297 Free PMC article. Clinical Trial.
32 results